Summary
Patients with stage II or stage III breast cancer treatable by surgery received neoadjuvant therapy with paclitaxel and trastuzumab with or without lapatinib. A mutational analysis on pretreatment tumors showed frequent mutations in TP53; these were associated with a greater rate of pathologic complete remission.
- neoadjuvant
- combination treatment
- mutational analysis
- stage 2
- stage 3
- trastuzumab
- lapatinib
- paclitaxel
- Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
- CALGB 40601
- NCT00770809
- © 2014 SAGE Publications
Tools
TP53 Mutations Are Associated With Increased Pathologic Complete Response in HER2-Positive BC
Permalink:
Table of contents
Cited By...
- No citing articles found.